Pharmaceuticals company Sun Pharmaceutical Industries announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Gross sales at Rs 128,156 million, growth of 8.5% India formulation sales at Rs 42,130 million, up 13.6% US formulation sales at USD 464 million, down 2.5% Global Specialty sales at USD 295 million, up 8.6%, accounting for 19.9% of Q4FY25 sales Emerging Markets formulation sales at USD 261 million, up 6.3% Rest of World formulation sales at USD 200 million, up 2.0% R&D; investments at Rs 8,166 million EBITDA at Rs 37,161 million (including other operating revenues), up 22.4%, with resulting EBITDA margin of 28.7% Adjusted net profit (excluding the exceptional items) for Q4FY25 was Rs 28,891 million, up 4.8%. Reported net profit for Q4FY25 was Rs 21,499 million compared to Rs 26,546 million during Q4FY24 FY25 Financial Highlights: Gross sales at Rs 520,412 million, growth of 9.0% India formulation sales at Rs 169,230 million, up 13.7% US formulation sales at USD 1,921 million, up 3.6% Global Specialty sales at USD 1,216 million, up 17.1%, accounting for 19.7% of FY25 sales Emerging Markets formulation sales at USD 1,114 million, up 7.0% Rest of World formulation sales at USD 847 million, up 4.5% EBITDA at Rs 152,717 million (including other operating revenues), up 17.3%, with resulting EBITDA margin of 29.0% Adjusted net profit (excluding the exceptional items) for FY25 was Rs 119,844 million, up 19.0%. Reported net profit for FY25 was Rs 109,290 million compared to Rs 95,764 million during FY24. Dilip Shanghvi, Chairman and Managing Director of the Company said, "Our businesses delivered a robust performance for the year, driven by improving market share in India and growth in Global Specialty. The nearterm pipeline in Global Specialty is promising, with products such as Leqselvi and Unloxcyt—the latter through our recently announced Checkpoint acquisition—offering significant improvements in patient care. We look forward to Specialty becoming an increasingly important part of our business." Result PDF